Last updated on February 2019

A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors

Brief description of study

This is a Phase I, two-stage, open-label, single-arm, dose escalation study of DFP-13318 intravenous infusion administered to patients with refractory or relapsed solid tumors. This study will explore two different dosing schedules- once every 3 weeks (q3w) and once every 2 weeks (q2w) - during Stage 1 and Stage 2, respectively.

Detailed Study Description

DFP-11318 is an investigational drug product that has demonstrated reasonable antitumor activity in preclinical colorectal, gastric and lung tumor models in animals. This is a first in human trial to determine the maximum, safest dose of DFP-11318 IV that can be administered to patients either once every 3 weeks or once every 2 weeks.

Clinical Study Identifier: NCT02646852

Find a site near you

Start Over